Trial Profile
An open-label, multicenter study to evaluate the efficacy and safety of a fixed-dose combination of abacavir 600 mg/lamivudine 300 mg once-daily in combination with atazanavir 300 mg + ritonavir 100 mg once-daily in antiretroviral-naive HIV-1 infected subjects with continuing evaluation of abacavir/lamivudine plus atazanavir 400 mg for maintenance over an additional 48 weeks
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Atazanavir (Primary) ; Lamivudine/abacavir (Primary) ; Ritonavir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms SHARE